

## SEQUENCE LISTING

BJ <110> Hornik, Vered

<120> CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED SOMATO  
STATIN ANALOGS

<130> 87534-3000

<140> 09/734,583

<141> 2000-12-13

<160> 10

<170> PatentIn version 3.1

<210> 1

<211> 14

<212> PRT

<213> mammalian

<400> 1

Ala	Gly	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10				14 <i>man</i>

<210> 2

<211> 6

<212> PRT

<213> Artificial peptide

<220>

<221> DISULFIDE BRIDGE

<222> (1)..(1)

<223> Cys residues at amino acid positions and 6 form a dis  
ulfide bridg  
e

<220>

<221> MOD\_RES

<222> (3)..(3)

<223> The Trp residue is the D isomer

Bf  
CONT.  
<400> 2

Cys Phe Trp Lys Thr Cys  
1 5

<210> 3  
<211> 6  
<212> PRT  
<213> Artificial peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> N-Methyl

<220>  
<221> MOD\_RES  
<222> (1)..(6)  
<223> cyclo

<220>  
<221> MOD\_RES  
<222> (3)..(3)  
<223> The Trp residue is the D isomer

<400> 3

Ala Tyr Trp Lys Val Phe  
1 5

<210> 4  
<211> 8  
<212> PRT  
<213> Artificial Peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> The Phe residue is a D isomer

B1  
Cont.

```

<220>
<221> MOD_RES
<222> (8)..(8)
<223> The Thr residue ends with CH2OH

```

```

<220>
<221> DISULFIDE BRIDGE
<222> (2)..(2)
<223> A disulfide bride is formed between Cys residues 2 an
d 7

```

```

<220>
<221> MOD_RES
<222> (2)..(2)
<223> The Trp residue is a D isomer

```

```

<400> 4

```

```

Phe Cys Phe Trp Lys Thr Cys Thr
1           5

```

```

<210> 5
<211> 7
<212> PRT
<213> Artificial Peptide

```

```

<220>
<221> DISULFIDE
<222> (2)..(2)
<223> A Disulfide Bridge is formed between the Cys residues
at position
      2 and 6

```

```

<220>
<221> MOD_RES
<222> (1)..(1)
<223> The Phe residue is a D isomer

```

```

<220>
<221> MOD_RES

```

BI  
Conf.

<222> (4)..(4)  
<223> The Trp residue is a D isomer

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> The Thr resiude ends with N2H

<400> 5

Phe Cys Phe Trp Lys Cys Thr  
1 5

<210> 6  
<211> 8  
<212> PRT  
<213> Artificial peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> is a gamma amino butyric acid, diamino butyric acid,  
Gly, beta-Al  
a, 5-amino pentanoic acid or amino hexanoic acid; Res  
idue 1 is bi  
rdged to Residue 8; Residue 1 also begins with a hydr  
ogen, or a m  
ono- or di- saccharide attached

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> is (D) or (L) Phe or Tyr

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> is (D) or (L)-Trp, or (L)-Phe, (D)- or (L)-1Nal or (D)  
) or (L)-2Na  
l, or Tyr

131  
cont

```

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> is (D) or (L)-Trp

```

```

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> is (D) or (L)-Lys

```

```

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> is Thr, Gly, Abu, Ser, Cys, Val, (D) or (L)-Ala, or (
D)- or (L)-A
      la, or Tyr

```

```

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> is (D) or (L)-Phe, or (D)- or (L)-Ala, Nle, or Cys;

```

```

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> is Gly, Val, Leu, (D) or (L)-Phe, or 1Nal or 2Nal; wi
th a termina
      1 carboxy acid, amide or alcohol group.

```

```

<400> 6

```

```

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1                               5

```

```

<210> 7
<211> 7
<212> PRT
<213> Artificial Peptide

```

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> is (D)- or (L)-Phe, or (D)- or (L)-Ala; wherein Resid  
 ue 1 is brid  
 ged to Residue 6 a bridging group composed of 1 to 5  
 methyl space  
 rs connected to an amide, thioether, thioester, or di  
 sulfide, fol  
 lowed by 1 to 5 methyl spacers

<220>  
 <221> MISC\_FEATURE  
 <222> (2)..(2)  
 <223> is Tyr or (D)- or (L)-Phe

<220>  
 <221> MISC\_FEATURE  
 <222> (3)..(3)  
 <223> is (D)- or (L)-Trp, (D)- or (L)-1Nal, or (D)- or (L  
 )-2Nal

<220>  
 <221> MISC\_FEATURE  
 <222> (5)..(5)  
 <223> is Thr, Val, Ser, or Cys

<220>  
 <221> MISC\_FEATURE  
 <222> (6)..(6)  
 <223> is Gly or (D)- or (L)-Phe

<220>  
 <221> MISC\_FEATURE  
 <222> (7)..(7)  
 <223> is Thr, GABA, (D)- or (L)-1Nal, (D)- or (L)-2Nal, or  
 (D)- or (L  
 )-Phe

<400> 7

Xaa Xaa Xaa Lys Xaa Xaa Xaa  
 1 5

<210> 8  
 <211> 9  
 <212> PRT  
 <213> Artificial Peptide

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> is absent or is a terminal group of one to four amino acids

<220>  
 <221> MISC\_FEATURE  
 <222> (2)..(2)  
 <223> is 1Nal, 2Nal, Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe

<220>  
 <221> MISC\_FEATURE  
 <222> (3)..(4)  
 <223> may be absent, or are independently Gly, Tyr, 1Nal, 2Nal, Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe

<220>  
 <221> MISC\_FEATURE  
 <222> (5)..(5)  
 <223> (D)- or (L)-Trp

<220>  
 <221> MISC\_FEATURE  
 <222> (6)..(6)  
 <223> (D)- or (L)-Lys

<220>  
 <221> MISC\_FEATURE  
 <222> (7)..(7)  
 <223> is absent or is Gly, Abu, Cys, Thr, Val, (D)- or (L)-  
 Ala, or (D)  
 - or (L)-Phe

<220>  
 <221> MISC\_FEATURE  
 <222> (8)..(8)  
 <223> is Cys, (D)- or (L)-Ala, or (D)- or (L)-Phe

<220>  
 <221> MISC\_FEATURE  
 <222> (9)..(9)  
 <223> is absent or is Val, Thr, 1Nal or 2Nal

<400> 8

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 1 5

<210> 9  
 <211> 7  
 <212> PRT  
 <213> Artificial Peptide

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> (D)- or (L)-Phe, Tyr or (D)- or (L)-Ala; Residue 1 i  
 s connected  
 to Residue 7 by a bridge comprised of 1 to 5 methylen  
 e spacers co  
 nnnected to an amide, thioether, thioester, or disulf  
 ide, followe  
 d by 1 to 5 methylene spacers

<220>  
 <221> MISC\_FEATURE  
 <222> (2)..(2)



<223> (D) - or (L) -Phe, Tyr or (D) - or (L) -Ala;

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> is absent or is (D) - or (L) -Phe, Tyr or (D) - or (L) -Ala;

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> is (D) - or (L) Tyr

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> is (D) - or (L) -Lys

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> is absent or is Thr, Val, Cys or (D) - or (L) -Ala

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> is a (D) - or (L) -Phe, Cys, or (D) - or (L) -Ala

<400> 9

Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1

5

<210> 10

<211> 7

<212> PRT

<213> Artificial Peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> is absent or is (D)- or (L)-Phe or Ala; the bridge is connected to Residue 1 or 2 and Residue 6 or 7, wherein the bridge is comprised of 1 to 5 methylene spacers connected to an amide, thioether, thioester, or disulfide, followed by 1 to 5 methylene spacers

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> is (D)- or (L)-Phe or Ala, Tyr

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> is (D)- or (L)-Trp

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> is (D)- or (L)-Lys

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> is Thr, Ala, Val, or Cys

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> is absent or is (D)- or (L)-Phe, Ala, or Cys

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> is absent or is Thr or Thr reduced to an alcoholol

<400> 10

Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5

BI  
Cenchrus